CP101
CP101-CDI-E02
Phase 2 mab completed
Quick answer
CP101 for Clostridium Difficile Infection is a Phase 2 program (mab) at Finch Therapeutics Group with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Finch Therapeutics Group
- Indication
- Clostridium Difficile Infection
- Phase
- Phase 2
- Modality
- mab
- Status
- completed